- Genetic Links to Anxiety and Depression
- EQUITy: Enhancing the quality of psychological interventions delivered by telephone
- COVID Anxiety Project (CAP)
- Mothers’ and fathers’ perceptions of their kids’ risky play: An online vignette study
- Investigating the Role of Mental Imagery in Obsessive-compulsive Disorder
- Living with depression and anxiety?
EQUITy: Enhancing the quality of psychological interventions delivered by telephone
The EQUITy programme is a £2.4 million research programme funded by the National Institute of Health Research’s Programme Grants for Applied Research funding stream. It aims to improve the way psychological therapies for depression and anxiety are delivered by telephone so that we can ensure that people receive the care that they need.
Depression and anxiety are common mental health problems that can cause substantial difficulties for people who experience them. The NHS has created an innovative psychological therapy service called Improving Access to Psychological Therapy (IAPT), to help people with these conditions. EQUITy is working closely with patients and professionals to ensure the work is acceptable to the people accessing IAPT services and those supporting patients.
If you would like to take part or would like further information about the programme you can email us at email@example.com.
Ends:1st October 2023
Genetic Links to Anxiety & Depression
Exciting new opportunity to engage in anxiety/depression research
Depression and anxiety are common but complex disorders whose research needs very large sample sizes. The Genetic Links to Anxiety and Depression (GLAD) study launches this September and aims to recruit >40,000 individuals. Anyone age 16 years or older who has experienced anxiety or depression during their lives can join this recontactable database to facilitate future research. Participants will also join a national Mental Health BioResource and contribute to the largest ever single study of anxiety and depression.
How can I take part?
All enrollment takes place online at our website, www.gladstudy.org.uk. An online animation explains the consent process with more detailed information in text format. Once you have provided consent and completed an online questionnaire you will be sent a saliva DNA sample kit to enable genetic studies.
We really hope you will join us in this important endeavour.
Covid Anxiety Project (CAP)
While it is normal to be worried about COVID, people with COVID anxiety become so worried they cannot function properly. These individuals spend a lot of time worrying about their health, and thinking about COVID may make them feel unwell or keep them awake at night.
Further information about the study can be found at: https://www.imperial.ac.uk/brain-sciences/research/psychiatry/covid-19-and-mental-health/
Ends 1st Dec 2021
Mothers’ and fathers’ perceptions of their kids’ risky play: An online vignette study
The CAPE (Childhood, Attachment, Play and Emotions) Lab at University of Sussex is conducting research that investigates the potential relationship between parental anxiety, child anxiety and children’s experiences of risky and adventurous play.
We are currently inviting UK resident mums and dads with a child aged 2-7 (not yet in Year 3) to complete an online study about their child’s risky and adventurous play.
The study will involve reading different risky and adventurous play scenarios and then answering questions about each scenario. You will also be asked questions about your beliefs about children’s risky play, your child’s engagement in risky and adventurous play, and how you supervise their play. Additionally, you’ll be asked some questions about you and your child’s feelings of anxiety and low mood.
The survey should take 30-45mins to complete and you can choose to provide your e-mail address to receive a £5 Amazon voucher for your participation.
You can access the survey here to find out more information and take part:
If you have any questions about taking part, feel free to contact the lead researcher, Toni Brown (firstname.lastname@example.org).
Investigating the Role of Mental Imagery in Obsessive-compulsive Disorder
Background of our study:
We are investigating the role of mental imagery in obsessive-compulsive disorder. Mental images are the pictures, sounds, smells, and other sensory information that run through our minds when we have a thought or feeling. Troubling mental imagery is understood to be an important feature of many mental health problems, and it is commonly reported by people who experience obsessive-compulsive disorder. However, to date there has been little research investigating the potential role that intrusive mental imagery plays in obsessive-compulsive disorder.
Aims of study:
We are hoping to develop a deeper understanding of how mental imagery may contribute to distress in obsessive and compulsive problems, with the hope of helping future research enhance treatments for people experiencing obsessive-compulsive disorder.
Who can participate?
We are interested in hearing from anyone aged 18 and over, as we are interested in hearing from people with a full range of experiences.
What will participants be asked to do?
Participants will be asked to complete a series of anonymous online questionnaires. These should take 20-30 minutes to complete.
For further information contact: –
Living with depression or anxiety?
Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious Distress with Suboptimal Response to Standard Antidepressants.
MAC understand that not all patients respond sufficiently well to current antidepressants and there is a need for more effective treatments for those with depression and anxiety. Therefore, MAC is currently conducting a clinical trial to evaluate an investigational drug for depression with anxious distress. Addressing anxiety symptoms in the context of depression may lead to improved outcomes for patients and more rapid relief of depression symptoms.
The purpose of this trial is to see if the investigational study drug is safe and effective for treating patients with Major Depressive Disorder (MDD) with anxious distress who have not had an adequate response to their current antidepressant medication. The study has a 1:1 ratio with placebo (dummy drug) and you will take the study medication for six weeks. You will stay on your current anti-depressant therapy throughout the trial.
This trial will run at our Barnsley, Liverpool, and Manchester sites.
Study Length: approximately 12 weeks.
No. of Visits: 7
Route of administration: Oral capsule.
Key inclusion criteria
• Male or female aged 18 – 64
• Diagnosis of depression with anxious distress
• Currently taking a stable dosage of eligible SSRI/SNRI
Key exclusion criteria
• A diagnosis of any major psychiatric condition including the following: delusions or hallucinations present along with depression, bipolar disorder, borderline personality disorder Schizophrenia, eating disorder, obsessive-compulsive disorder
• History of MS, optic neuritis or any demyelinating disease
This is not a complete list of qualifying criteria.
A full description of the study will be given before you decide to take part, both over the phone and during an appointment at a MAC clinic. This will include you receiving the full patient information sheet (PIS).Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with your treating physician.
Barnsley: +44 (0) 1226 356940 Liverpool: +44 (0) 151 4824700 Manchester: +44 (0) 161 2759966
Contact Alex Billington email@example.com